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Abstract
The relapse rate for children with acute myeloid leukemia is nearly 40% despite aggressive chemotherapy and often stem cell
transplant. We sought to understand how environment-induced signaling responses are associated with clinical response to
treatment. We previously reported that patients whose AML cells showed low G-CSF-induced STAT3 activation had inferior
event-free survival compared to patients with stronger STAT3 responses. Here, we expanded the paradigm to evaluate multiple signaling parameters induced by a more physiological stimulus. We measured STAT3, STAT5 and ERK1/2 responses
to G-CSF and to stromal cell-conditioned medium for 113 patients enrolled on COG trials AAML03P1 and AAML0531.
Low inducible STAT3 activity was independently associated with inferior event-free survival in multivariate analyses. For
inducible STAT5 activity, those with the lowest and highest responses had inferior event-free survival, compared to patients
with intermediate STAT5 responses. Using existing RNA-sequencing data, we compared gene expression profiles for patients
with low inducible STAT3/5 activation with those for patients with higher inducible STAT3/5 signaling. Genes encoding
hematopoietic factors and mitochondrial respiratory chain subunits were overexpressed in the low STAT3/5 response groups,
implicating inflammatory and metabolic pathways as potential mechanisms of chemotherapy resistance. We validated the
prognostic relevance of individual genes from the low STAT3/5 response signature in a large independent cohort of pediatric
AML patients. These findings provide novel insights into interactions between AML cells and the microenvironment that
are associated with treatment failure and could be targeted for therapeutic interventions.
Keywords Pediatric AML · STAT3 · STAT5 · Microenvironment · Bone marrow stroma · Inflammation
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Children with acute myeloid leukemia (AML) are treated
with aggressive regimens that often include stem cell
transplantation, yet event-free survival (EFS) rates remain
approximately 60% [1, 2]. Current risk assignment algorithms incorporate cytogenetics, various somatic mutations,
and residual disease after one cycle of chemotherapy [3].
This strategy misses a substantial fraction of patients who
need more intensive therapy, because 20–30% of “low-risk”
patients relapse [1, 4]. At the other end of the spectrum,
25–30% of high-risk patients who are transplanted in first
remission die of relapse or toxicity [5, 6]. Our goal is to
define AML-microenvironment interactions that contribute
to relapse and can be targeted pharmacologically.
Signal transducer and activator of transcription 3 (STAT3)
and STAT5 mediate signals from hematopoietic factors in
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the bone marrow, including G-CSF, GM-CSF, IL-6, IL-3,
and others. In general, these signals promote proliferation
and survival. Aberrant STAT3/5 activity is found in numerous malignancies and confers resistance to chemotherapy
and targeted inhibitors [7–9]. In studies of AML specimens
from adults, robust activation of STAT3 and STAT5 is associated with induction failure [10, 11]. In children, however,
weak activation of STAT3 is associated with inferior EFS
[12, 13]. This difference between adult and pediatric AML at
the functional level is consistent with many differences at the
molecular level [14]. Therefore, efforts to develop prognostic
biomarkers and targeted therapies need to be informed by
the unique biology of the pediatric disease.
Here, we evaluated signaling responses and gene expression profiles for patients who were treated on the Children’s
Oncology Group trials AAML03P1 and AAML0531. We
quantified signaling responses to individual factors and to
HS5 stromal cell-conditioned medium (CM). Since HS5
cells secrete dozens of hematopoietic factors, CM more
closely recapitulates the bone marrow soluble factor milieu.
We found that STAT3 and STAT5 responses were associated with EFS in this contemporary patient population. Further, we identified genes that were differentially expressed
between cases that did and did not activate these pathways.
These genes suggest biological features that may contribute
to relapse and represent therapeutic opportunities.

Methods
Cells
Cryopreserved bone marrow specimens from 159 pediatric
patients with de novo AML were obtained from the Children’s Oncology Group (COG) Biopathology Center, and
6 from the Texas Children’s Hospital Research Tissue Support Service. All COG patients were enrolled on the treatment protocols AAML03P1 or AAML0531. Patient families
gave written informed consent, in accordance with the Declaration of Helsinki, for banking of bone marrow for future
research. The treatment regimens and outcomes for these
trials have been reported [1, 15]. Bone marrow samples were
enriched for mononuclear cells by density centrifugation and
cryopreserved. These studies were approved by the Institutional Review Board of Baylor College of Medicine.
The human AML cell line Kasumi-1 served as the positive control for flow cytometry studies. Kasumi-1 cells were
obtained from ATCC and grown in RPMI 1640 (ATCC)
with 10% fetal bovine serum (FBS; Invitrogen), 2 mM
L-glutamine, 100 units/ml penicillin and 100 μg/ml streptomycin (pen/strep; Invitrogen). The HS5 cell line was purchased from ATCC and maintained in DMEM with 10%
FBS, 2 mM L-glutamine and pen/strep. Kasumi-1 and HS5
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cells were grown in a humidified 37 °C incubator with 5%
CO2. For HS5-conditioned medium (CM), HS5 cells were
seeded at 105 cells/ml and allowed to attach overnight.
Medium was then replaced with RPMI + additives and collected after 48 h. CM was centrifuged to remove cells and
stored at − 20 °C. CM stocks were thawed only once. Cell
lines were authenticated by STR profiling annually.

Flow cytometry
Samples were thawed and evaluated for viability as previously described [13]. Only samples with at least 60%
viability and sufficient cell number were processed. Ultimately, 122 COG samples and 4 local samples were suitable for analysis. Cells were distributed at 2–3 × 105 cells/
well for stimulation; control wells remained unstimulated.
Stimulation with individual factors included G-CSF (10 ng/
ml); IL-6 + soluble IL-6 receptor α (sIL-6R; 5 + 10 ng/
ml, respectively); GM-CSF (1 ng/ml); and IL-3 (5 ng/ml).
G-CSF (filgrastim) was purchased from the Texas Children’s
Hospital Pharmacy and the others were from R&D Systems. For CM stimulation, 0.5 ml CM was added to AML
cells suspended in 0.5 ml fresh medium, to yield 50% CM.
After 15 min, cells were fixed, permeabilized, and stained
for FACS as described [16]. Antibodies for flow cytometry
were purchased from BD Biosciences unless otherwise
noted, and included CD45-APC-H7 (clone 2D1); cleaved
PARP (cPARP)-AlexaFluor 647 or AlexaFluor 700 (clone
F21-852); pY-STAT3-PE (clone 4/P); pY-STAT5-PerCPCy5.5 or -AlexaFluor 647 (clone 47); pY-ERK1/2-Pacific
Blue (clone 197G2; Cell Signaling Technologies); CD116BV421 (clone M1); CD123-APC (clone 7G3); and CD131AlexaFluor 647 (clone 3D7). Data were acquired with Diva
on a customized 5-laser LSRII (BD) and analyzed with FCS
Express v6 (DeNovo). Gating steps isolated viable blasts,
based on FSC v SSC, CD45dim, and cPARPneg (Fig. 1a).

Gene expression analyses
Existing RNA-sequencing (RNA-seq) databases were mined
for this study. The RNA-seq count data were imported, normalized and analyzed using the RNA-seq function of BRB
ArrayTools [17]. Unreliable low-count transcripts in all samples were filtered. Then, a differential expression analysis
of the specified STAT3/5 response classes was performed
based on the edgeR quasi-likelihood pipeline with sample
batch correction [18]. The genes were called significant at
false discovery rate (FDR) = 0.05. Upstream regulator and
pathway analyses were conducted using Ingenuity Pathway
Analysis software (Qiagen). The upstream regulator analysis
is based on prior knowledge of expected effects between
regulators and targets in the Ingenuity Knowledge Base.
The analysis identified the targets of different regulators in
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Fig. 1  Pediatric AML samples showed variable pY-STAT3 and pYSTAT5 responses to stimulation. a The gating strategy involved isolation of blasts and exclusion of lymphocytes based on CD45 v. SSC,
followed by exclusion of non-viable (cPARP +) cells. Signaling pathway activation was quantified for viable blasts. The ΔMFI was calcu-

lated as the MFI for stimulated cells/MFI for unstimulated cells. b–d
Primary pediatric AML samples were stimulated with G-CSF (10 ng/
ml; n = 111), IL-6 + sIL-6R (5 ng + 10 ng/ml; n = 111), 50% CM
(n = 113) or vehicle. Activated pY-STAT3, pY-STAT5, and pERK1/2
were measured by flow cytometry. The red bar indicates the mean

the RNA-seq dataset and compared the direction of change
of a target gene with the expected change in the literature.
Then, activation z-score is calculated to infer predicted activation or inactivation states of the upstream regulators relative to the random assignments. Activation z-score >  = 2 is
called activated. The overlap p-value evaluates if the overlap
between the differentially expressed genes and known targets
regulated by a regulator is significant.

test. Five-year estimates of event-free (EFS) and overall
survival (OS) from study entry were calculated by the
Kaplan–Meier method. Estimates are reported with two
times the Greenwood standard error. OS is defined as time
from study entry to death from any cause. EFS is defined
as time from study entry to induction failure, relapse, or
death from any cause. EFS and OS were compared for
significant differences by the log-rank test. The Cox proportional hazards model was used to estimate hazard ratios
(HR) and to determine the prognostic value of the ligand
response categories. Exploratory multiple cutpoint analyses were performed by estimating the HR for OS and EFS
by examining all cutpoints between 10 and 90% quantile
levels of each marker and comparing the lower versus
higher groups for each cutpoint.
Analyses of the relationships between gene expression
levels and EFS were conducted for 1061 patients enrolled
on AAML1031, with clinical data through March 31,
2020. RNA-seq data in transcripts per million (TPM) were
available from the TpAML project. Cases were separated
into quartiles and outcomes compared as described above.

Statistics
Statistical analysis of signaling data was performed using
Prism 5.02 (GraphPad Software Inc., La Jolla, CA, USA).
Values are means ± standard error of the mean (SEM). A
two-tailed Pearson correlation analysis was used to assess
the degree of relationship between two continuous variables.
Clinical data were analyzed through September 30,
2015 for AAML03P1 patients and through June 30, 2019
for AAML0531 patients. The significance of observed differences in proportions was tested using the Chi-squared
test and Fisher’s exact test when data were sparse. Comparisons of medians were tested using the Kruskal–Wallis
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Results
A subset of pediatric AML cases failed to activate
STAT3/5 signaling in response to multiple stimuli
We studied diagnostic specimens from pediatric AML
patients enrolled on the COG trials AAML03P1 or
AAML0531. Both studies used the same chemotherapy
backbone. Patients on AAML03P1 and AAML0531 arm B
also received gemtuzumab ozogamicin [1, 15]. The 5-year
EFS and OS for the 113 patients with both HS5 CM response
data and outcome data were 50.9 ± 9.6% and 65.6 ± 9.2%,
respectively. The 5-year EFS and OS for all other eligible
patients on these trials (n = 1248) were 49.2 ± 2.9% and
63.9 ± 2.8%, respectively. These survival rates are not significantly different, confirming that the study cohort is clinically representative of the pediatric AML population.
Most prior studies of signaling responses in leukemia
cells used single factors. To more accurately represent the
microenvironment, we stimulated AML cells with HS5
CM. Previously, we quantified soluble factors in both HS5
CM [19] and bone marrow plasma from pediatric AML
patients [20]. The factor levels present in 50% CM are
within the range of levels in AML bone marrow plasma
for 32 of 41 factors (Online Resource Table S1), including
IL-3, IL-6, G-CSF, and GM-CSF.
We quantified the signaling responses to G-CSF, IL-6
and 50% CM using our established flow cytometry assay.
We evaluated phosphotyrosine-STAT3 (pY-STAT3) and
pY-STAT5, given their anti-apoptosis effects and associations with patient outcome [10]. For comparison, we
also evaluated pERK1/2 (pT202/pY204) responses to the
same stimuli. We quantified responses as the fold change
in mean fluorescence intensity for the stimulated condition over the unstimulated condition (∆MFI, Fig. 1a). Figure 1b–d illustrates the ranges of inducible pY-STAT3,
pY-STAT5, and pERK1/2 responses.
Pearson correlations of ∆MFIs revealed that each signaling parameter responded similarly to different stimuli
(Fig. 2). The pY-STAT3 responses were especially consistent between different stimuli, with correlation coefficients
0.79–0.85 (p < 0.0001). A sample that strongly activated
STAT3 with G-CSF also strongly activated STAT3 with IL-6
and CM, whereas samples that failed to increase pY-STAT3
in response to individual ligands also failed to respond to
CM. Interestingly, the correlation between G-CSF-activated pY-STAT5 and CM-activated pY-STAT5 was weak
(r = 0.24), suggesting that CM contains factors that activate
STAT5 independently of its activation by G-CSF. The pYSTAT3 and pY-STAT5 responses to a given stimulus were
moderately correlated (Pearson r = 0.38–0.51), and a subset
of samples responded poorly in both parameters.
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Given the variability between G-CSF-induced pY-STAT5
and CM-induced pY-STAT5, we measured responses to GMCSF and IL-3 in 13 additional samples. GM-CSF and IL-3
activate pY-STAT5 but not pY-STAT3, and they use the
same CD131 co-receptor. The GM-CSF- and IL-3-induced
pY-STAT5 responses were strongly correlated with a Pearson coefficient of 0.75 (Online Resource Fig. S1). The pYSTAT5 responses to GM-CSF and IL-3 were weakly correlated with pY-STAT5 responses to CM. We again noted
cases that failed to activate pY-STAT5 downstream of multiple stimuli. Therefore, while physiological STAT5 activity
reflects multiple upstream ligands, a subset of cases remains
uniformly unresponsive.
To determine whether samples that failed to active
STAT3/5 pathways also failed to activate a mechanistically
different pathway, we also measured inducible pERK1/2
(Fig. 1d) [12, 21]. Each sample’s pERK1/2 responses
to the different stimuli were positively correlated (Pearson r = 0.37–0.75), and there were samples that failed to
activate pERK1/2 in response to any stimuli. However,
pERK1/2 ∆MFIs did not correlate with pY-STAT3 or pYSTAT5 downstream of any of the stimuli (Fig. 2b), indicating that samples with failed STAT3 or STAT5 activation
could still activate ERK1/2, and vice versa. Therefore, the
mechanism(s) accounting for dysfunctional STAT3/5 signaling are likely different from those underlying dysfunctional
pERK1/2 signaling.

Failure to respond to stimulation was not related
to basal activation or receptor expression
One possible explanation for aberrant pY-STAT3/5 activation is that the pathway is highly constitutively activated,
precluding further inducible activation. Unstimulated pYSTAT3 and pY-STAT5 levels were generally low and only
weakly inversely correlated with the ligand-induced ∆MFI
(Online Resource Fig. S2a), arguing against this explanation. Another possible explanation for failed signaling is low
receptor expression. Previously, we showed that G-CSFinduced pY-STAT3 was positively correlated with G-CSF
receptor expression, but IL-6-induced pY-STAT3 was
inversely correlated with gp130 expression [13]. Here, we
measured the expression of CD116 and CD123, the alpha
receptor subunits for GM-CSF and IL-3, respectively, and
their common beta receptor subunit, CD131, for the same
13 samples with which these ligand responses were evaluated (Online Resource Fig. S2b). Expression of CD116 and
CD123 were variable and not related to ligand-induced
pY-STAT5 (Online Resource Fig. S2c-d). CD131 surface
expression was uniformly low, as has been reported [22].
Therefore, the signaling dysfunction noted in a subset of
pediatric AML cells cannot be attributed to elevated constitutive activation nor to absence of surface receptors.
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Fig. 2  Ligand-induced pY-STAT3 and pY-STAT5 responses were
strongly correlated. a The pY-STAT3 ΔMFIs in response to G-CSF
and CM were strongly correlated. (n = 111), as were the pY-STAT3
and pY-STAT5 ΔMFIs in response to CM stimulation (n = 113).

r = Pearson correlation coefficient. b The heatmap illustrates the
degree of correlation for each ligand-induced signaling parameter
with the others. Numbers represent the Pearson correlation coefficient
(r)

Environment‑induced pY‑STAT3 and pY‑STAT5 were
associated with EFS

cutpoint. There was no significant difference in OS between
groups (54.2 ± 20.3% v. 68.4 ± 10.3%; p = 0.244; Online
Resource Fig. S3a). IL-6-induced pY-STAT3 was not associated with EFS in this cohort, nor in the CCG2961 group.
For CM-induced pY-STAT3, patients whose AML cells
had ∆MFI ≤ 1.76 (n = 33) had a 5-year EFS of 36.4 ± 16.7%
(Fig. 3b), compared to the 80 patients whose AML cells
responded above this threshold (57.2 ± 11.4%, p = 0.051).
The OS did not differ significantly between groups
(57.1 ± 17.4% v. 69.2 ± 10.8%; p = 0.172; Online Resource
Fig. S3b). The relationship between inducible pY-STAT5
and EFS was more complex. We did not find an association
between G-CSF-induced pY-STAT5 and EFS in this study or
previously. For CM-induced pY-STAT5, the cutpoint analysis discriminated three groups (Fig. 3c). Patients with failed
pY-STAT5 (∆MFI ≤ 1.18, n = 28) and patients with robust

In our analysis of samples from patients treated on
CCG2961, patients whose AML cells had a G-CSF-induced
pY-STAT3 ∆MFI < 2 had an inferior EFS compared to
patients with pY-STAT3 ∆MFI ≥ 2 [13]. We first independently validated this association in pediatric AML patients
treated with contemporary regimens. We performed cutpoint analyses to identify a threshold that best discriminated patients with good and poor outcomes. For G-CSFinduced pY-STAT3 (Fig. 3a), patients whose AML cells
had a ∆MFI ≤ 1.5 had an inferior EFS (n = 24; 5-year EFS
29.2 ± 18.6%) compared to patients whose AML cells had
a ∆MFI > 1.5 (n = 87; 5-year EFS 56.4 ± 10.8%; p = 0.044).
This result confirms our prior observation with a similar
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intermediate-response group (p = 0.009; Online Resource
Fig. S3c). These results demonstrate that aberrant ligandinduced STAT3 or STAT5 signaling identifies patients with
poor EFS.

STAT3/5 signaling patterns were associated with age
and core binding factor fusions

Fig. 3  Inducible pY-STAT3 and pY-STAT5 were associated with
outcome. a Kaplan–Meier survival curves show that patients whose
AML cells had a G-CSF-induced pY-STAT3 ΔMFI ≤ 1.5 (n = 24) had
a 5-year EFS of 29.2 ± 18.6%, compared to 56.4 ± 10.8% for patients
with a ΔMFI > 1.5 (n = 87; p = 0.044). b Patients whose AML cells
had a CM-induced pY-STAT3 ΔMFI ≤ 1.76 (n = 33) had a 5-year
EFS of 36.4 ± 16.7%, compared to those whose AML cells responded
above this threshold (n = 80; 57.2 ± 11.4%, p = 0.051). c Patients
with CM-induced pY-STAT5 MFI ≤ 1.18 (n = 28) and patients with
CM-induced pY-STAT5 MFI > 2.25 (n = 12) had 5-year EFS of
28.6 ± 17.1% and 33.3 ± 27.2%, respectively, compared to the patients
in the intermediate-response group (n = 73; 62.8 ± 11.6%; p < 0.001)

pY-STAT5 (∆MFI > 2.25, n = 12) had poorer survival rates
(5-year EFS of 28.6 ± 17.1% and 33.3 ± 27.2%, respectively),
compared to patients in the intermediate-response group
(n = 73; 5-year EFS 62.8 ± 11.6%; p < 0.001). The 5-year OS
was 45.5 ± 19.1% for the low-response group, 58.3 ± 28.5%
for the high-response group, and 75.0 ± 10.6% for the
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The low pY-STAT3/5 response groups were enriched for
infants age < 2 yr (Online Resource Tables S2–S3). This
finding is interesting because infants have different cytogenetic fusions than patients in older age groups [14]. As
has been reported [13, 23], the higher pY-STAT3 response
groups were enriched for patients with core binding factor fusions t(8;21) and inv(16) (Online Resource Table S2),
which confer a favorable prognosis. We also saw enrichment
of M2 morphology in the high pY-STAT3 response groups,
suggesting that the level of differentiation may be related to
the signaling phenotype [24, 25]. Almost half of the patients
in the highest STAT5 response category had FLT3/ITD
(Online Resource Table S3). The association between FLT3/
ITD, STAT5 activity, and poor outcome is well established
[26, 27], although the contribution of environment-induced
pY-STAT5 to poor survival in this group of patients has not
been elucidated.
Univariable Cox models for EFS supported the results
of the Kaplan–Meier comparisons (Table 1). Patients with
low G-CSF-induced pY-STAT3 and low CM-induced pYSTAT3 had approximately a 70% higher risk of having
an event (induction failure, relapse, or death) compared
to those with higher G-CSF and CM-induced pY-STAT3
(p = 0.047 and 0.054, respectively). Patients with low CMinduced pY-STAT5 were more than twice as likely to have
an event (p = 0.001), and those with the highest CM-induced
pY-STAT5 were more than three times as likely to have an
event (p = 0.001), compared to patients with CM-induced
pY-STAT5 responses in the intermediate range. Only low
CM-induced pY-STAT5 response was a significant factor
for OS. For relevant clinical variables, patients with lowrisk cytomolecular features [t(8;21), inv(16), CEBPα mutation, NPM1 mutation] had HRs below 0.3 for EFS and OS
(p < 0.001), while age and presenting WBC were not significant factors.
The multivariable models for EFS and OS combining
each STAT response group with age, presenting WBC and
cytomolecular risk group are presented in Table 2. Low
CM-induced pY-STAT3 was a significant adverse factor
(p = 0.028). CM-induced pY-STAT5 retained strong prognostic value with event HRs > 3 for the low- and highresponse groups (p = 0.001). A low CM-induced pY-STAT5
response was also an adverse factor for OS (p = 0.008).
Therefore, impaired environment-induced STAT3/5 activation is a clinically relevant phenotype that can identify
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Univariable
N

EFS from study entry
HR

G-CSF-induced pY-STAT3 ∆MFI
> 1.5
87
1
<  = 1.5
24
1.79
CM-induced pY-STAT3 ∆MFI
> 1.76
80
1
<  = 1.76
33
1.71
CM-induced pY-STAT5 ∆MFI
1.18–2.25
73
1
<  = 1.18
28
2.61
> 2.25
12
3.45
Age at dx (in years)
>  = 2
103
1
0–1
10
0.93
WBC (× 103/MicroL)
≤ 100
89
1
> 100
24
1.59
Cytomolecular risk
Standard
30
1
Low
63
0.29
High
18
1.23

pediatric AML patients at higher risk of treatment failure,
independent of cytomolecular features.
While the empirically determined cutpoints differed
somewhat between signaling parameters, we saw substantial
overlap in the lists of patients in the low-response groups.
There were 14 patients in both the low G-CSF-induced pYSTAT3 (n = 21) and the low CM-induced pY-STAT3 (n = 33)
response groups and 24 patients in both the low CM-induced
pY-STAT3 and the low CM-induced pY-STAT5 response
groups (n = 30). We were particularly intrigued by the 11
patients (~ 10%) who belonged to all 3 low-response groups.
These patients and their clinical characteristics are presented
in Table 3. Notably, only 3 (27%) had not experienced an
event at last follow-up. Seven of the 8 patients with an event
experienced relapse or refractory disease.

Cases with low pY‑STAT3/5 response phenotypes
had increased expression of genes encoding
hematopoietic factors and respiratory chain
proteins
Existing RNA-seq data were available for 68 of the 113
cases (60%) used for the survival analyses. We identified
371 transcripts that were differentially expressed in samples
with G-CSF-induced pY-STAT3 ∆MFI ≤ 1.5 compared to
samples with ∆MFI > 1.5, at FDR = 0.05 (Online Resource

95% CI

OS from study entry
p

HR

95% CI

p

1.01–3.17

0.047

1
1.52

0.75–3.07

0.247

0.99–2.95

0.054

1
1.58

0.81–3.08

0.176

1.45–4.70
1.61–7.38

0.001
0.001

1
2.79
2.25

1.39–5.59
0.83–6.09

0.004
0.113

0.37–2.34

0.881

1
0.85

0.26–2.76

0.785

0.88–2.87

0.128

1
0.80

0.35–1.81

0.585

0.16–0.53
0.63–2.42

< 0.001
0.546

1
0.23
0.79

0.11–0.51
0.36–1.77

< 0.001
0.571

Table S4). All but 39 were upregulated in the low-response
group. Similarly, we identified 350 transcripts that were
differentially expressed in the low CM-induced pY-STAT3
group, compared to the samples in the higher response group
(Online Resource Table S5). All but 11 were higher in the
low-response group. We identified 302 transcripts that were
differentially expressed between the low and intermediate
CM-induced pY-STAT5 groups, with all but 19 higher in
the low-response group (Online Resource Table S6). The
transcriptomes of the high and intermediate CM-induced
pY-STAT5 groups were very similar, with only 2 differentially expressed transcripts identified.
After excluding transcripts that did not map to a known
gene, we identified 87 genes that were commonly upregulated in the low G-CSF-induced pY-STAT3 and the low
CM-induced pY-STAT3 response groups, compared to
their corresponding high-response groups (Online Resource
Table S7). We identified 152 genes that were commonly differentially expressed in the CM-induced pY-STAT3 and CMinduced pY-STAT5 response comparisons, of which 151
were higher in the low-response groups (Online Resource
Table S8). Finally, 42 genes were commonly upregulated in
all 3 low-response groups (Table 4). Interestingly, a number
of genes encoding hematopoietic soluble factors were commonly upregulated in all 3 low-response groups, including
CSF2 (GM-CSF), CSF3 (G-CSF), CCL20 (MIP-3α) and
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Multivariable with G-CSF-induced pY-STAT3
N

EFS from study entry
HR

95% CI

G-CSF-induced pY-STAT3 ∆MFI
> 1.5
85
1
<  = 1.5
24
1.43
0.77–2.66
Age at dx (in years)
>  = 2
99
1
0–1
10
0.34
0.12–0.98
WBC (× 103/MicroL)
≤ 100
86
1
> 100
23
1.87
0.93–3.75
Cytomolecular risk
Standard
29
1
Low
62
0.21
0.10–0.42
High
18
0.75
0.33–1.67
Multivariable with CM-induced pY-STAT3
CM-induced pY-STAT3 ∆MFI
> 1.76
78
1
<  = 1.76
33
1.99
1.08–3.67
Age at dx (in years)
>  = 2
101
1
0–1
10
0.37
0.13–1.04
WBC (× 103/MicroL)
≤ 100
88
1
> 100
23
2.23
1.10–4.52
Cytomolecular risk
Standard
30
1
Low
63
0.23
0.11–0.45
High
18
0.94
0.42–2.14
Multivariable with CM-induced pY-STAT5
CM-induced pY-STAT5 ∆MFI
1.18–2.25
71
1
<  = 1.18
28
3.10
1.61–5.99
> 2.25
12
3.65
1.66–8.02
Age at dx (in years)
>  = 2
101
1
0–1
10
0.33
0.12–0.92
WBC (× 103/MicroL)
≤ 100
88
1
> 100
23
2.32
1.15–4.66
Cytomolecular risk
Standard
30
1
Low
63
0.19
0.09–0.39
High
18
0.84
0.38–1.86

CCL22 (MDC). This result is not explained by a difference
in the proportion of non-malignant cells in the low-responding samples since the blast percentages were similar between
groups (Online Resource Table S2). Notably, 3 components
of the mitochondrial electron transport chain (ETC) complex
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OS from study entry
p

HR

95% CI

p

0.257

1
1.13

0.54–2.39

0.744

0.046

1
0.44

0.12–1.61

0.214

0.078

1
0.74

0.28–1.95

0.538

< 0.001
0.478

1
0.20
0.69

0.09–0.46
0.27–1.73

< 0.001
0.427

0.028

1
1.47

0.73–2.94

0.282

0.060

1
0.46

0.13–1.67

0.239

0.026

1
0.76

0.28–2.01

0.576

< 0.001
0.889

1
0.22
0.80

0.09–0.49
0.31–2.05

< 0.001
0.646

0.001
0.001

1
2.79
2.01

1.31–5.95
0.72–5.60

0.008
0.182

0.035

1
0.38

0.10–1.40

0.145

0.019

1
0.96

0.36–2.58

0.938

< 0.001
0.672

1
0.22
0.81

0.10–0.51
0.32–2.04

< 0.001
0.652

I (NDUFA3, NDUFA6, NDUFA13) were increased in all 3
low-response groups. Ingenuity Pathway Analysis of the 42
common genes identified functions related to proliferation,
inflammation and transcription (Online Resource Table S9).
String, a protein-based algorithm, also identified networks
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Table 3  Patients included in all 3 low-response groups (n = 11)
USI

Age (years) Sex BM blast% Cytogenetics

PANXWX
PAPBEJ
PARWXU
PARXMP

7.5921
1.0048
1.526
1.463

F
F
M
M

81
50
91% (PB)
35

PASLTF
PASMYS
PASXDS
PASXVC
PASYDA
PASYWA
PATGIY

16.8569
2.1027
15.6797
20.3751
13.9329
14.1848
5.321

M
F
M
M
M
M
M

81
47
37
71
32
95
66

t(9;11) ( +)
del(7q)( +)
del(11p)
Complex;
NUP98KDM5A
NK
+8
NK
NK
NK
NK
t(6;11)

FLT3

Mutations

Risk assignment SCT in CR1? First event

WT
WT
WT
WT

None
None
None
None

Standard
Standard
Standard
Standard

Unknown
No
No
No

Induction failure
Relapse
Relapse
Censored

WT
WT
PM
ITD 0.37
ITD 0.19
ITD 0.93
WT

CEBPα
NPM1, WT1, KIT
NPM1
NPM1
NPM1
None
None

Low
Low
Low
Low
Low
High
Standard

No
No
No
Yes
Yes
Unknown
Yes

Censored
Relapse
Censored
Relapse
Death in CR
Induction failure
Relapse

USI unique subject identifier, WT wild-type, ITD internal tandem duplication, PM point mutation, SCT stem cell transplant, CR1 first complete
remission

with hematopoietic factors and respiratory chain proteins at
the hubs (Online Resource Fig. S4).
Using the upstream regulator function of the Ingenuity
Pathway Analysis [28], we identified upstream regulatory
programs that could account for the gene signature associated with low environment-induced STAT3 and STAT5
activation. Activation of pro-inflammatory cytokines
(TNFα, IL-1β and IL-17A) and their downstream mediators (NFKBIZ) are statistically associated with the observed
low STAT3/5 response gene expression profile (Table 4).
Consistent with the increased expression of ETC complex
1 genes, we further identified CD36 as a likely upstream
regulator. CD36 is a scavenger receptor that takes up longchain fatty acids to fuel mitochondrial fatty acid oxidation
in chemoresistant AML cells [29, 30]. Therefore, our findings suggest that pediatric AML cases with low inducible
STAT3/5 may derive their chemotherapy resistance from
specific inflammatory interactions and energy production
processes.

Genes highly expressed by low STAT3/5 response
cases were associated with poor prognosis
in an independent pediatric AML dataset
To evaluate the prognostic relevance of genes that were
overexpressed in the low-response groups, we queried the
TpAML dataset, which includes RNA-seq data for 1061
pediatric AML patients who enrolled in the COG phase III
trial AAML1031 [3]. Two of the three genes encoding respiratory chain complex I subunits, NDUFA3 and NDUFA6,
demonstrated significantly worse EFS for patients with
higher expression compared to those with lower expression
(Fig. 4a, b). Patients with higher expression of CAVIN3,
which encodes a caveolae-associated protein that regulates

endocytosis, had significantly inferior EFS (Fig. 4c). Patients
with higher expression of ANKRD37, a target gene of the
hypoxia sensor HIF1α, had significantly inferior outcomes
compared to patients with lower expression (Fig. 4d). These
transcriptome comparisons reveal candidate genes for further studies that will elucidate mechanisms of aberrant environment-mediated signaling and of treatment failure.

Discussion
In this study of pediatric AML patients enrolled on contemporary COG trials, we demonstrated that aberrantly
low STAT3 and STAT5 responses to multiple environmentderived factors are associated with inferior EFS. Patients
whose AML cells demonstrated aberrantly low STAT3 activation upon stimulation with stromal cell CM had inferior
outcomes compared to patients with a stronger inducible
STAT3 response. Likewise, patients with aberrantly low
CM-induced pY-STAT5 had significantly inferior EFS.
The prognostic relevance of CM-induced STAT3/5 activity retained significance in multivariate modeling taking
into account cytomolecular risk, age, and presenting WBC.
Therefore, the phenotype of low environment-induced
STAT-pathway signaling is a novel and independent functional prognostic factor in pediatric AML.
A recent study of inducible STAT3/5 signaling in pediatric AML patients by Schumich, et al., did not find a relationship between G-CSF-induced pY-STAT3 and outcome
[23]. Importantly, their survival analysis did not include
patients classified as low risk, whereas in our study, it was
those patients with low-risk cytogenetics who tended to
have high G-CSF-induced pY-STAT3 (∆MFI > 1.5; Online
Resource Table S2). The same study reported that higher
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Table 4  Commonly upregulated genes in all 3 low-response groups
Gene

ADIRF
ANKRD37
ANOS1
BCYRN1
CAVIN3
CCL20
CDC42BPA
CDO1
CENPW
CSF2
CSF3
CSKMT
DKK1
DNAAF1
ELOB
ESRRG
HILPDA
HPSE2
HSD11B1-AS1
IL23A
IL4I1
IL6
IL6R-AS1
LY6K
LYPD3
NDUFA13
NDUFA3
NDUFA6
PNMA5
PPP1R17
PPP1R27
PTGES
SNHG25
ST6GALNAC5
STARD10
TEX15
TNFAIP6
TNFRSF9
TRPC6
VTRNA1-3
YJEFN3
ZNF687-AS1
Top upstream regulators
Upstream regulator
CD36
IL1B
IL17A
NFKBIZ

13

G-CSF-induced pY-STAT3

CM-induced pY-STAT3

CM-induced pY-STAT5

FDR

Log2FC (low/high)

FDR

Log2FC (low/high)

FDR

Log2FC (low/mid)

< 1e-4
0.015
0.0014
< 1e-4
0.0032
< 1e-4
0.0055
4.00E-04
8.00E-04
< 1e-4
< 1e-4
2.00E-04
0.0222
< 1e-4
0.0089
2.00E-04
< 1e-4
0.0301
< 1e-4
< 1e-4
< 1e-4
< 1e-4
< 1e-4
0.0397
< 1e-4
0.0184
0.0133
0.0154
4.00E-04
< 1e-4
1.00E-04
< 1e-4
0.0301
0.0031
0.0093
0.0032
< 1e-4
5.00E-04
0.0156
0.0019
0.0236
0.0026

6.5744
1.7141
5.2994
4.3908
4.688
6.9573
4.422
3.7092
1.53
5.2173
8.3887
2.6544
4.7557
7.4279
1.3216
7.4727
3.8202
7.8146
3.9508
5.2571
3.1947
4.8538
4.2896
2.9021
3.4425
1.1661
1.5326
1.0439
4.196
6.1809
4.9516
4.6081
1.5205
4.9639
1.3999
6.4781
2.8495
2.4794
7.4776
3.4363
1.0885
1.8023

< 1e-4
0.0023
0.0043
< 1e-4
0.027
< 1e-4
6.00E-04
0.0049
0.0316
4.00E-04
< 1e-4
< 1e-4
0.0013
< 1e-4
0.0109
8.00E-04
< 1e-4
< 1e-4
0.0083
< 1e-4
1.00E-04
0.0011
0.0011
0.0291
2.00E-04
0.0294
0.036
0.0487
0.0086
0.0043
0.0077
0.0062
0.0322
< 1e-4
0.0044
0.0059
0.0011
0.0158
< 1e-4
0.0011
0.0316
0.017

5.9897
1.8159
5.1466
4.3853
4.1479
6.3836
3.7621
3.2727
1.0592
4.8279
7.8638
2.7212
4.3437
6.796
1.1885
6.3846
3.3193
8.5754
3.1905
4.8305
2.4834
4.1393
3.4554
2.9798
2.9239
1.028
1.3075
0.8535
3.6158
5.0882
4.3288
3.4467
1.4285
4.651
1.3516
3.7189
2.3017
1.8904
6.0442
3.4755
0.9716
1.5161

0.001
0.0085
< 1e-4
0.0023
4.00E-04
< 1e-4
0.0085
0.0195
0.0362
0.0068
3.00E-04
< 1e-4
< 1e-4
< 1e-4
0.0456
0.0417
0.0011
< 1e-4
0.0217
1.00E-04
0.0054
0.0109
0.0099
0.0393
0.0071
0.0193
0.0098
0.0417
0.0251
0.0484
0.0023
0.0307
0.0366
0.0039
0.0328
0.013
0.0099
0.0307
< 1e-4
0.0219
0.0215
0.0364

5.6125
1.6901
5.916
3.6507
4.5154
6.2951
3.4334
3.1027
1.1481
3.9251
7.3808
2.7129
5.9058
6.5581
1.1028
6.4541
3.2191
8.5329
3.0611
4.5209
2.219
3.9563
3.1758
2.8443
2.5933
1.1314
1.525
0.9218
3.513
4.3184
4.3348
3.1158
1.4536
4.1388
1.194
3.7723
2.1905
1.8416
5.7396
2.8717
1.0585
1.4661

Predicted state
Activated
Activated
Activated
Activated

Activation z-score
2
2.104
2.122
2.177

p overlap
1.38E-06
2.38E-08
2.54E-07
4.56E-11
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Table 4  (continued)
Gene

TNF

G-CSF-induced pY-STAT3

CM-induced pY-STAT3

CM-induced pY-STAT5

FDR

FDR

FDR

Log2FC (low/high)
Activated

Log2FC (low/high)
2.372

Log2FC (low/mid)
3.13E-04

Fig. 4  Genes from the 42-gene low-response signature have prognostic value in pediatric AML. a, b Two genes encoding respiratory
chain complex I subunits, NDUFA3 and NDUFA6, demonstrated significantly worse EFS for patients with expression levels in the highest quartile (Q4), compared to those with lower expression. c Patients
with expression of the signaling regulator CAVIN3 in the highest

quartile (Q4) had significantly lower EFS than those in quartiles 1–3.
d Patients with expression of the HIF1α target ANKRD37 in quartiles
2–4 had significantly inferior outcomes compared to patients with
expression in the lowest quartile (Q1). Kaplan–Meier estimates are
based on clinically annotated RNA-seq data for 1061 patients in the
TpAML dataset. Log-rank p-values are shown

GM-CSF-induced pY-STAT5 was associated with higher
relapse risk. We found that very high and very low CMinduced pY-STAT5 responses were associated with poor
EFS. Schumich, et al., also measured pY-STAT5 induced
by a cytokine cocktail, but they did not report on any relationships between those responses and outcome.
The association between STAT3/5 activation and EFS
also has been studied in adult AML patients. Notably,
the results for pediatric patients are the opposite of those
reported for adult AML patients [10, 11]. The difference in
signaling pathway biology between adults and children is

yet another example of how pediatric AML is different from
adult AML. Thousands of adult and pediatric AML cases
have been characterized at the molecular level, revealing
numerous differences between age groups [14, 31–34]. Our
results show that adult and pediatric AML cells also differ
functionally.
Further, our results suggest that mechanisms that blunt
STAT3 signaling also blunt STAT5, and these mechanisms
are independent of the ligand-receptor interaction itself. The
IL-6, IL-3 and GM-CSF receptors are comprised of alpha
and beta subunits that colocalize with downstream mediators
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in specialized membrane domains containing clathrin, caveolin, or specific lipids (e.g. lipid rafts). Internalization of the
ligand-receptor complex is an important step in signaling
and also regulates receptor surface expression (as recently
reviewed [35, 36]). Defective membrane domain organization or endocytosis could explain intact receptor surface
expression but decreased signaling activity downstream of
multiple ligands, as we saw in our samples.
The dysfunction that accounts for low inducible STAT3/5
signaling could also contribute to poor outcomes. For
instance, extrinsic apoptosis signaling also requires organization of signaling components in lipid rafts, so a generalized lipid raft dysfunction could explain aberrantly low
signaling and aberrantly low apoptosis. Another explanation
could be that AML cells that activate STAT3/5 are more proliferative, whereas AML cells that do not activate STAT3/5
are more quiescent and thereby resistant to drugs that kill
dividing cells. Further studies are required to determine the
mechanisms explaining the relationship between signaling
responses and patient outcomes.
We recognize that CM-induced signaling responses are
not likely to be developed for clinical testing, but a corresponding gene signature could more readily be clinically
validated. We identified a number of genes that were differentially expressed between patients in the low-response
groups compared to those in the higher response groups.
Interestingly, several genes encoding hematopoietic factors
were paradoxically upregulated in the low-response groups.
It is possible that the feedback pathways that normally limit
factor expression are not engaged when ligand-induced signaling is impaired. Several genes encoding adhesion signaling components also were upregulated in the low-response
groups. Adhesion to the microenvironment is a well-known
mechanism by which malignant cells derive protection from
cytotoxic chemotherapy [37].
To unify the differentially expressed genes into physiological processes, we identified their common upstream
regulators. Here, multiple pro-inflammatory factors—TNFα,
IL-1β, IL-17A, and NFKBIZ—were revealed to be potential drivers of the gene expression profile associated with
low inducible STAT3/5. This finding is important in several
ways. First, expression of these inflammatory mediators by
AML cells is driven by their adhesion to stromal cells [38,
39], reinforcing the concept that cases with low inducible
STAT3/5 signaling are likely to derive their chemoresistance
from alternative, contact-dependent survival pathways. Second, IL-17A not only drives inflammation but also recruits
myeloid-derived suppressor cells [40], and thus may contribute to the poor outcomes of these patients by promoting
immune evasion. Third, these inflammatory pathways are
targetable. Secukinumab is a monoclonal antibody against
IL-17A that is FDA-approved for the treatment of psoriasis. TNF inhibitors, including etanercept, infliximab and
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adalimumab, are FDA-approved for the treatment of multiple
inflammatory conditions like rheumatoid arthritis.
We also identified metabolism genes among those upregulated in cases with low STAT3/5 activation. Specifically,
genes encoding ETC complex 1 proteins were expressed
more highly in those cases. Additionally, CD36 was identified as a likely upstream regulator. CD36 is a fatty acid
translocase that takes up substrates for mitochondrial fatty
acid oxidation and is expressed on leukemia stem cells [29].
Several recent studies have demonstrated that AML cells
that survive chemotherapy depend on oxidative phosphorylation [30, 41]. Indeed, AML cells that survived cytarabine
had increased expression of CD36, and blocking fatty acid
oxidation with etomoxir sensitized AML cells to cytarabineinduced apoptosis in vitro [30]. Other drugs that interfere
with oxidative phosphorylation have shown promise in preclinical [42] and clinical studies [43].

Conclusion
Our data demonstrate that aberrant inducible STAT3/5
signaling identifies a subset of pediatric AML patients with
inferior EFS, independent of cytomolecular features. AML
cells from these patients are further characterized by a specific gene expression profile that suggests an inflammatory
bone marrow microenvironment and dependence on oxidative metabolism. Taken together, our results reveal potential
mechanisms of chemotherapy resistance that can be targeted
to improve outcomes.
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